Pharmaceutical

GSK and CureVac restructure mRNA vaccine development deal

GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.

Jul 4, 2024 - 04:00
GSK and CureVac restructure mRNA vaccine development deal
GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.
Read the original article

Tags:

Previous Article

EMA approves Sanofi’s Dupixent for COPD treatment in adults

Next Article

Protecting your drug products: Strategies for preventing metal contamination in ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Abdera raises funds to advance radiopharmaceuticals to treat cancer

Abdera raises funds to advance radiopharmaceuticals to ...

Apr 20, 2023

AFM-24I by Affimed for Metastatic Hepatocellular Carcin...

Feb 8, 2024

Apple and Masimo face off in trial over patient monitoring patents

Apple and Masimo face off in trial over patient monitor...

Apr 5, 2023